Integrum AB (publ) (INTEG-B.ST)
SEK 18.65
(3.04%)
SEK 18.65
(3.04%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 6.51 Million SEK | 103.5% |
| 2022 | -19.7 Million SEK | -1996.88% |
| 2021 | 1.03 Million SEK | 156.08% |
| 2020 | -1.85 Million SEK | 88.19% |
| 2019 | -15.68 Million SEK | 36.2% |
| 2018 | -24.57 Million SEK | -30.92% |
| 2017 | -18.77 Million SEK | -206.22% |
| 2016 | -6.13 Million SEK | -3293.31% |
| 2015 | 192 Thousand SEK | 124.12% |
| 2014 | -796 Thousand SEK | -126.38% |
| 2013 | 3.01 Million SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -11.98 Million SEK | -557.07% |
| 2023 Q2 | 6.45 Million SEK | 320.65% |
| 2023 FY | 690.56 Thousand SEK | 103.5% |
| 2023 Q1 | -2.92 Million SEK | 59.21% |
| 2023 Q4 | -1.82 Million SEK | -130.0% |
| 2023 Q3 | 6.08 Million SEK | -5.79% |
| 2022 Q2 | 873 Thousand SEK | 138.52% |
| 2022 Q1 | 366 Thousand SEK | 181.84% |
| 2022 FY | -19.7 Million SEK | -1996.88% |
| 2022 Q4 | -7.17 Million SEK | 47.93% |
| 2022 Q3 | -13.77 Million SEK | -1677.66% |
| 2021 Q2 | -243 Thousand SEK | -120.49% |
| 2021 Q1 | 1.18 Million SEK | 138.22% |
| 2021 FY | 1.03 Million SEK | 156.08% |
| 2021 Q4 | -447.21 Thousand SEK | -188.91% |
| 2021 Q3 | 503 Thousand SEK | 307.0% |
| 2020 Q3 | 1.25 Million SEK | -59.39% |
| 2020 FY | -1.85 Million SEK | 88.19% |
| 2020 Q4 | -3.1 Million SEK | -348.07% |
| 2020 Q2 | 3.08 Million SEK | 200.0% |
| 2020 Q1 | -3.08 Million SEK | 31.8% |
| 2019 Q4 | -4.51 Million SEK | -15.67% |
| 2019 FY | -15.68 Million SEK | 36.2% |
| 2019 Q1 | -4.85 Million SEK | 43.5% |
| 2019 Q2 | -2.4 Million SEK | 50.51% |
| 2019 Q3 | -3.9 Million SEK | -62.46% |
| 2018 FY | -24.57 Million SEK | -30.92% |
| 2018 Q4 | -8.59 Million SEK | -1.93% |
| 2018 Q3 | -8.43 Million SEK | -338.51% |
| 2018 Q2 | -1.92 Million SEK | 65.83% |
| 2018 Q1 | -5.62 Million SEK | 19.96% |
| 2017 Q1 | -1.18 Million SEK | 80.93% |
| 2017 FY | -18.77 Million SEK | -206.22% |
| 2017 Q4 | -7.03 Million SEK | 10.56% |
| 2017 Q3 | -7.86 Million SEK | -191.98% |
| 2017 Q2 | -2.69 Million SEK | -126.31% |
| 2016 Q3 | -1.55 Million SEK | 22.15% |
| 2016 Q1 | 3.65 Million SEK | 972.82% |
| 2016 FY | -6.13 Million SEK | -3293.31% |
| 2016 Q2 | -1.99 Million SEK | -154.6% |
| 2016 Q4 | -6.23 Million SEK | -301.09% |
| 2015 Q4 | 341 Thousand SEK | 139.25% |
| 2015 Q3 | -868.75 Thousand SEK | 0.0% |
| 2015 FY | 192 Thousand SEK | 124.12% |
| 2014 FY | -796 Thousand SEK | -126.38% |
| 2013 FY | 3.01 Million SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Acarix AB (publ) | -77.55 Million SEK | 108.397% |
| ADDvise Group AB (publ) | 300.6 Million SEK | 97.834% |
| ADDvise Group AB (publ) | 300.6 Million SEK | 97.834% |
| Arcoma AB | 4.66 Million SEK | -39.75% |
| Bactiguard Holding AB (publ) | -131.93 Million SEK | 104.936% |
| BICO Group AB (publ) | -618.3 Million SEK | 101.053% |
| Boule Diagnostics AB (publ) | 39.27 Million SEK | 83.417% |
| CellaVision AB (publ) | 167.05 Million SEK | 96.102% |
| Clinical Laserthermia Systems AB (publ) | -65.93 Million SEK | 109.877% |
| Chordate Medical Holding AB (publ) | -29.57 Million SEK | 122.022% |
| C-Rad AB (publ) | 44.24 Million SEK | 85.281% |
| Duearity AB (publ) | -25.76 Million SEK | 125.278% |
| Dignitana AB (publ) | -15.02 Million SEK | 143.34% |
| Episurf Medical AB (publ) | -94.8 Million SEK | 106.87% |
| Getinge AB (publ) | 3.81 Billion SEK | 99.829% |
| Scandinavian Real Heart AB (Publ) | -68.44 Million SEK | 109.515% |
| Iconovo AB (publ) | -45.77 Million SEK | 114.226% |
| Luxbright AB (publ) | -25.8 Million SEK | 125.237% |
| Mentice AB (publ) | -679 Thousand SEK | 1059.108% |
| OssDsign AB (publ) | -91.95 Million SEK | 107.082% |
| Paxman AB (publ) | 12.61 Million SEK | 48.393% |
| Promimic AB (publ) | -9.11 Million SEK | 171.423% |
| Qlife Holding AB (publ) | -168.69 Million SEK | 103.86% |
| SciBase Holding AB (publ) | -53.93 Million SEK | 112.074% |
| ScandiDos AB (publ) | -13.48 Million SEK | 148.3% |
| Sectra AB (publ) | 518.49 Million SEK | 98.744% |
| Sedana Medical AB (publ) | -65.54 Million SEK | 109.935% |
| Senzime AB (publ) | -133.74 Million SEK | 104.869% |
| SpectraCure AB (publ) | -21.35 Million SEK | 130.501% |
| Stille AB | 44.95 Million SEK | 85.513% |
| Vitrolife AB (publ) | -3.58 Billion SEK | 100.181% |
| Xvivo Perfusion AB (publ) | 38.5 Million SEK | 83.087% |